Product Images Docetaxel

The text describes a figure labeled as "Figure 3", which shows survival K-M Curves of TAX317 between Docetaxel 75 mg/m? and Best Supportive Care. It indicates the cumulative probability and survival time in months. The overall survival is represented by Log-rank p of 0.010.*

The text is describing a figure labelled "Figure 4 - TAX320 Survival K-M Curves", which compares the overall survival rates of patients treated with Docetaxel 75 mg/m2 to those who received Vinorelbine or Ifosfamide Control. The graph shows a log-rank p-value of 0.13 and survival rates over a range of 0-21 months.*

The text is describing a graph that shows the survival probability of patients over time using the TAX327 Survival K-M Curves. The x-axis represents time in months and the y-axis represents survival probability. The graph shows the survival probability decreasing over time. The text also includes numbered tick marks on the y-axis ranging from 3 to 10, likely representing percentages or fractions.*

The text is a description of a figure labeled "Figure 6 - Gastric Cancer Study (TAX325) Time to Progression K-M Curve." The figure shows a graph with a Y-axis labeled "Probability (%)" and an X-axis labeled "Time (months)." The graph appears to depict the time to progression of gastric cancer in the study, but the details are not available due to the limited information provided by the text.*

The text describes a figure labeled as "Figure 7 - Gastric Cancer Study (TAX325) Survival K-M Curve". The figure presents a survival probability K-M (Kaplan-Meier) curve for a study on gastric cancer. The y-axis shows the survival probability in percentages, and the x-axis shows the survival time in months. The curve starts at 100% at month 0 and decreases over time, reaching 3% at month 27.*

The text describes a Figure 8 called "TAX323 Progression-Free Survival K-M Curve". The figure presents a curve that shows the probability of Progression-Free Survival (PFS) over time, in months, from 0 to 36. The axis of PFS probability ranges from 0% to 100%.*

The text describes a figure labeled as "Figure 9 -TAX323 Overall Survival K-M Curve" presenting the survival probability percentage (%) over time (in months). The x-axis represents the survival time in months, while the y-axis represents the survival probability percentage (%). The figure demonstrates the results of TAX323's overall survival using K-M Curve analysis.*

This is a medication description for Docetaxel, an injection used for intravenous use only. It comes in a multiple-dose vial that should be protected from light and stored at 20° to 25°C. Each mL contains 10mg Docetaxel, a cytotoxic agent used to treat cancer, along with Polysorbate 80 NF, Anhydrous Citric Acid USP, Dehydrated Alcohol USP, and Polyethylene Glycol 300 NF. The medication should be checked for concentration prior to preparation and administered according to the included instructions. The product is manufactured by Ingenus Pharmaceuticals in Switzerland and the lot number is 431-08 v4/12-2020.*

This is a description for Docetaxel Injection, a cytotoxic agent that comes in a multiple-dose vial. It is meant for intravenous use only and should be added to an infusion solution. The available dosage is 80 mg/8 mL, or 10 mg/mL. The package contains complete instructions, and caution should be taken while handling it. The concentration should be checked before preparation. It should be stored between 20-25°C and protected from light. The manufacturer is Ingenus Pramacoutcas LLC.*

This appears to be a combination of a few different texts. The first part seems to be a list of various codes and numbers, not provided in context. The second part is a description of a medication called Docetaxel Inj, which comes in a sterile, multiple-dose vial and is meant for intravenous use only. The medication contains 160 mg per 16 mL, with a concentration of 10 mg per mL. It is recommended to check concentration prior to preparation and see the package insert for complete instructions.*

Docetaxel Injection is a cytotoxic agent intended for intravenous use only. The multi-dose vial contains 160 mg/16 mL (10 mg/mL) of the active ingredient. To prepare for use, one must first take into account the concentration of the product. The solution must be stored between 20-25°C and protected from light. The manufacturer warns that this product is a cytotoxic agent and should be handled with care. The package has complete instructions for proper preparation and usage.*